

This Section of *Epidemiology and Psychiatric Sciences* regularly appears in each issue of the Journal to describe relevant studies investigating the relationship between neurobiology and psychosocial psychiatry in major psychoses. The aim of these Editorials is to provide a better understanding of the neural basis of psychopathology and clinical features of these disorders, in order to raise new perspectives in every-day clinical practice.

Paolo Brambilla, *Section Editor* and Michele Tansella, *Editor EPS*

Brain anatomy of major depression II. Focus on amygdala

M. Bellani^{1*}, M. Baiano² and P. Brambilla^{3,4}

¹ Department of Public Health and Community Medicine, Section of Psychiatry and Clinical Psychology, Inter-University Center for Behavioural Neurosciences (ICBN), University of Verona, Verona, Italy

² Center for Weight and Eating Disorders, Portogruaro, Venice, Italy

³ DISM, Section of Psychiatry, Inter-University Center for Behavioural Neurosciences (ICBN), University of Udine, Udine, Italy

⁴ IRCSS “E. Medea” Scientific Institute, Udine, Italy

Here, we briefly summarize the most consistent structural magnetic resonance imaging (MRI) studies on amygdala in major depression and debate the effects of clinical variables on amygdalar morphology.

Received 23 August 2010; Revised 30 August 2010; Accepted 30 August 2010

Key words: Major depressive disorder, magnetic resonance imaging (MRI), volumes.

Major depressive disorder (MDD) has been associated with morphological changes of medial temporal lobe's structures, particularly of the amygdala, possibly being part of an altered limbic–thalamic–cortical circuitry (Zou *et al.* 2010; Bellani *et al.* 2010). This structure is part of the ventral limbic system and is functionally connected to the prefrontal cortex, cingulate gyrus and hypothalamus. It is a key component for affective modulation (such as negative emotions and fear), memory encoding and social behaviour (Baxter & Murray, 2002). Several magnetic resonance imaging (MRI) studies have found reduced amygdala volumes in patients suffering from depression (Sheline *et al.* 1998, 1999; Campbell *et al.* 2004; Hickie *et al.* 2007), specifically in children (Rosso *et al.* 2005), unmedicated (Caetano *et al.* 2004; Tang *et al.* 2007; Kronenberg *et al.* 2009), multiple episode (Bremner

et al. 2000; Caetano *et al.* 2004; Hastings *et al.* 2004; Monkul *et al.* 2007), psychotic and female patients (Sheline *et al.* 1999; Hastings *et al.* 2004; Tang *et al.* 2007; Keller *et al.* 2008; Lorenzetti *et al.* 2009). In this regard, chronic or recurrent MDD patients are persistently exposed to stress-induced glucocorticoids, which may have neurotoxic effects, potentially leading to amygdala shrinkage (Hamidi *et al.* 2004). Interestingly, slight volume reductions of amygdalar grey matter have been shown over time without significant gross abnormalities (Frodl *et al.* 2008a, b), suggesting the presence of subtle microstructural processes occurring during a depression episode and after recovery. However, other structural investigations have shown preserved volumes (Mervaala *et al.* 2000; Munn *et al.* 2007; MacMaster *et al.* 2008), mainly in current non-suicidal patients (Monkul *et al.* 2007), in non-psychotic depressed patients (Keller *et al.* 2008) or in recovered patients (van Eijndhoven *et al.* 2009; Lorenzetti *et al.* 2010). Moreover, enlarged amygdalar volumes have also been reported (van Elst *et al.* 2000), particularly in subjects using antidepressants (Frodl *et al.* 2003; Weniger *et al.* 2006)

* Address for correspondence: Dr. M. Bellani, Department of Public Health and Community Medicine, Section of Psychiatry and Clinical Psychology, University of Verona, Piazzale L.A. Scuro, 10 - 37134 Verona, Italy.
(Email: marcella.bellani@univr.it, paolo.brambilla@uniud.it)

Table 1. Cross-sectional and follow-up studies investigating amygdalar volumetry in adult patients with MDD compared with healthy control subjects

Study	HC	MDD subjects	Type of MDD	MRI methods	Significant findings
Sheline <i>et al.</i> (1998)	20	20 (F) outpatients, mean age: 54.0	Remission	Stereological methods, 1.5 T	Core amygdala: MDD < HC
Sheline <i>et al.</i> (1999)	24	24 (F) outpatients, 16 AD, mean age: 52.8	Recurrent	Stereological methods, 1.5 T	Core amygdala: MDD < HC
Bremner <i>et al.</i> (2000)	16	16 (10 M/6 F) outpatients, 16 AD, mean age: 43.0	Remission	ROI manual tracing, 1.5 T	R amygdala: MDD < HC
Mervaala <i>et al.</i> (2000)		34 (16M/18F) inpatients, mean age: 42.2	Drug-resistant	ROI manual tracing; 1.5 T	Total amygdala: MDD = HC MDD: R amygdala < L amygdala
van Elst <i>et al.</i> (2000)	20	17 (6 M/11 F), mean age: 32.8	Dysthymia	ROI manual tracing, 1.5 T	Total amygdala: MDD > HC
Von Gunten <i>et al.</i> (2000)	14	14 (6 M/8 F), 10 AD, mean age: 57.0	Recurrent	ROI manual tracing, 1.5 T	L amygdala: MDD < HC
Frodl <i>et al.</i> (2003)	57	57 (27 M/30 F) inpatients, 57 AD, mean age: 44.5	First episode and recurrent	ROI manual tracing, 1.5 T	Total amygdala: first episode MDD > HC and recurrent MDD recurrent MDD = HC
Caetano <i>et al.</i> (2004)	31	31 (7 M/24 F), mean age: 39.2	Current and remitted MDD episode	ROI manual tracing, 1.5 T	L Amygdala GM: MDD < HC total amygdala: current MDD = remitted MDD
Hastings <i>et al.</i> (2004)	18	18 (8 M/10 F) outpatients, mean age: 39.8	Current	ROI manual tracing, 1.5 T	R amygdala: MDD < HC only for females
Lange & Irlle (2004)	17	17 (F) inpatients, mean age: 34.0	Current	Three dimensional MRI, 1.5 T	Total amygdala: MDD > HC
Rosso <i>et al.</i> (2005)	24	20 (3 M/17 F), mean age: 15.3	Recent onset	ROI manual tracing, 1.5 T	Total amygdala: MDD < HC
Weniger <i>et al.</i> (2006)	23	21 (F) inpatients, 21 AD, mean age: 34.0	Recent onset	ROI manual tracing, 1.5 T	Total amygdala: MDD > HC
Hickie <i>et al.</i> (2007)	16	45 (15 M/30 F), mean age: 52.8	Current	ROI manual tracing, 1.5 T	Total amygdala: MDD < HC
Monkul <i>et al.</i> (2007)	17	17 (F), mean age: 34.4	Suicidal and non-suicidal	ROI manual tracing, 1.5 T	R amygdala: suicidal MDD > non-suicidal MDD total amygdala: non suicidal MDD = HC
Munn <i>et al.</i> (2007)	18 TP	26 (F) twins+ 24 HR (F), mean age: 20.6	Current and HR subjects	ROI manual tracing, 1.5 T	Total amygdala: MDD = HC
Tang <i>et al.</i> (2007)	13	14 (F), mean age: 29.5	First episode	VBM, 1.5 T	Total amygdala: MDD < HC
Frodl <i>et al.</i> (2008a)*	30	30 (11 M/19 F) inpatients. Baseline (t0): 29 AD, 3 years (t1): 25 AD, mean age: 45.0	Current MDD	ROI manual tracing, 1.5 T	Total amygdala: no significant decrease
Frodl <i>et al.</i> (2008b)*	30	38 (13 M/25 F) inpatients, baseline (t0): 37 AD 3 years (t1): 23 AD, mean age: 46.1	Current	VBM, 1.5 T	L amygdala grey matter: MDD < HC during the 3 year follow-up
Keller <i>et al.</i> (2008)	22	42 (19 M/23 F) outpatients, 24 AD, mean age: 36.5	Psychotic and non-psychotic	ROI manual tracing, 3 T	Total amygdala: psychotic MDD < HC non-psychotic MDD = HC.
MacMaster <i>et al.</i> (2008)	35	32 (12 M/20 F), mean age: 14.8	Current with familiar MDD	ROI manual tracing, 1.5 T	Total amygdala: MDD = HC

Continued

Table 1. Continued

Study	HC	MDD subjects	Type of MDD	MRI methods	Significant findings
Kronenberg <i>et al.</i> (2009)	14	24 inpatients, mean age: 54.5	Current	ROI manual tracing, 1.5 T	Total amygdala: MDD < HC
van Eijndhoven <i>et al.</i> (2009)	20	40 (13 M/27 F) outpatients, mean age: 34.9	Current and recovered first episode	ROI manual tracing, 1.5 T	Total Amygdala: current first episode MDD > recovered MDD recovered MDD = HC
Lorenzetti <i>et al.</i> (2010)	31	56 (16 M/40 F) outpatients, 33 AD, mean age: 33.7	Current and remitted	ROI manual tracing, 1.5 T	L Amygdala: remitted MDD > current MDD and HC L amygdala: current MDD = HC R amygdala: current MDD = remitted MDD = HC

*Follow-up studies: AD, patients on antidepressants at the time of the MRI scanning; HC, healthy control subjects; HR, high risk; L, left; R, right; ROI, region of interest; T, twins; VBM, voxel-based-morphometry; M, male; F, female.

and in those with severe illness or at the early stage of the disease (Frodl *et al.* 2003, 2008a; Lange & Irlé, 2004; Lorenzetti *et al.* 2010; Weniger *et al.* 2006).

In summary, although there is some evidence that amygdala size is reduced in MDD patients, particularly in those with recurrent episodes (Hamilton *et al.* 2008; Lorenzetti *et al.* 2009), preserved and increased volumes have also been reported. The heterogeneity of the results summarized here (see Table 1) may in part be due to socio-demographical and clinical differences of the samples (age of onset, single or multiple episodes, familiar history of MDD, medication, psychotic symptoms and phases of the illness) (Hajek *et al.* 2009). Furthermore, the proximity of the amygdala to the head of the hippocampus makes the anatomical delineation of this structure difficult. Indeed, as reported in the meta-analysis by Campbell *et al.* (2004), MRI studies considering the amygdala-hippocampus complex revealed no significant differences between depressed and control subjects. In order to better clarify the role of amygdala for the pathophysiology of MDD, future MRI studies should explore amygdala morphology in large sample of drug-naïve patients at their first episode of depression in comparison with matched healthy individuals, longitudinally following them after recovery.

References

- Baxter MG, Murray EA (2002). The amygdala and reward. *Nature Reviews Neuroscience* **3**, 563–573.
- Bellani M, Baiano M, Brambilla P (2010). Brain anatomy of major depression I. Focus on hippocampus. *Epidemiologia e Psichiatria Sociale* **19**, 298–301.
- Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS (2000). Hippocampal volume reduction in major depression. *American Journal of Psychiatry* **157**, 115–117.
- Caetano SC, Hatch JP, Brambilla P, Sassi RB, Nicoletti M, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC (2004). Anatomical MRI study of hippocampus and amygdala in patients with current and remitted major depression. *Psychiatry Research: Neuroimaging* **132**, 141–147.
- Campbell S, Marriott M, Nahmias C, MacQueen GM (2004). Lower hippocampal volume in patients suffering from depression: a meta-analysis. *American Journal of Psychiatry* **161**, 598–607.
- Frodl T, Jäger M, Smajstrlova I, Born C, Bottlender R, Palladino T, Reiser M, Möller HJ, Meisenzahl E (2008a). Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3 year prospective magnetic resonance imaging study. *Journal of Psychiatry and Neuroscience* **33**, 423–430.
- Frodl T, Meisenzahl EM, Zetsche T, Born C, Jäger M, Groll C, Bottlender R, Leinsinger G, Möller HJ (2003). Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. *Biological Psychiatry* **53**, 338–344.
- Frodl TS, Koutsouleris N, Bottlender R, Born C, Jäger M, Scupin I, Reiser M, Möller HJ, Meisenzahl EM (2008b). Depression related variation in brain morphology over 3 years. Effects of stress? *Archives of General Psychiatry* **65**, 1156–1165.
- Hajek T, Kopeck M, Kozeni J, Gunde E, Martin A, Höschl C (2009). Amygdala volumes in mood disorders. A meta-analysis of magnetic resonance volumetry studies. *Journal of Affective Disorders* **115**, 395–410.
- Hamidi M, Drevets WC, Price JL (2004). Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. *Biological Psychiatry* **55**, 63–59.
- Hamilton JP, Siemer M, Gotlib IH (2008). Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. *Molecular Psychiatry* **13**, 993–1000.
- Hastings RS, Parsey RV, Oquendo MA, Arango V, Mann JJ (2004). Volumetric analysis of the prefrontal cortex, amygdala, and hippocampus in major depression. *Neuropsychopharmacology* **29**, 952–959.

- Hickie IB, Naismith SL, Ward PB, Scott EM, Mitchell PB, Schofield PR, Scimone A, Wilhelm K, Parker G (2007). Serotonin transporter gene status predicts caudate nucleus but not amygdala or hippocampal volumes in older persons with major depression. *Journal of Affective Disorders* **98**, 137–142.
- Keller J, Shen L, Gomez RG, Garrett A, Brent Solvason H, Reiss A, Schatzberg AF (2008). Hippocampal and amygdala volumes in psychotic and nonpsychotic unipolar depression. *American Journal of Psychiatry* **165**, 872–880.
- Kronenberg G, Tebartz van Elst L, Regen F, Deuschle M, Heuser I, Colla M (2009). Reduced amygdala volume in newly admitted psychiatric in-patients with unipolar major depression. *Journal of Psychiatric Research* **43**, 1112–1117.
- Lange C, Irle E (2004). Enlarged amygdala volume and reduced hippocampal volume in young women with major depression. *Psychological Medicine* **34**, 1059–1064.
- Lorenzetti V, Allen NB, Fornito A, Yücel M (2009). Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies. *Journal of Affective Disorders* **117**, 1–17.
- Lorenzetti V, Allen NB, Whittle S, Yücel M (2010). Amygdala volumes in a sample of current depressed and remitted depressed patients and healthy controls. *Journal of Affective Disorders* **120**, 112–119.
- MacMaster FP, Mirza Y, Szeszko PR, Kmiecik LE, Easter P, Taormina SP, Lynch M, Rose M, Moore GJ, Rosenberg DR (2008). Amygdala and hippocampal volumes in familial early onset major depressive disorder. *Biological Psychiatry* **63**, 385–390.
- Mervaala E, Föhr J, Könönen M, Valkonen-Korhonen M, Vainio P, Partanen K, Partanen J, Tiihonen J, Viinamäki H, Karjalainen AK, Lethonen J (2000). Quantitative MRI of the hippocampus and amygdala in severe depression. *Psychological Medicine* **30**, 117–125.
- Monkul ES, Hatch JP, Nicoletti MA, Spence S, Brambilla P, Lacerda ALT, Sassi RB, Mallinger AG, Keshavan MS, Soares JC (2007). Fronto-limbic brain structures in suicidal and non-suicidal female patients with major depressive disorder. *Molecular Psychiatry* **62**, 360–366.
- Munn MA, Alexopoulos J, Nishino T, Babb CM, Flake LA, Singer T, Ratnanather JT, Huang H, Todd RD, Miller MI, Botteron KN (2007). Amygdala volume analysis in female twins with major depression. *Biological Psychiatry* **62**, 415–422.
- Rosso IM, Cintron CM, Steingard RJ, Renshaw PF, Young AD, Yurgelun-Todd DA (2005). Amygdala and hippocampus volumes in pediatric major depression. *Biological Psychiatry* **57**, 21–26.
- Sheline YI, Gado MH, Price JL (1998). Amygdala core nuclei volumes are decreased in recurrent major depression. *Neuroreport* **9**, 2023–2028.
- Sheline YI, Sanghavi M, Mintun MA, Gado MH (1999). Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. *Journal of Neuroscience* **19**, 5034–5043.
- Tang Y, Wang F, Xie G, Liu J, Li L, Su L, Liu Y, Hu X, He Z, Blumberg HP (2007). Reduced ventral anterior cingulate and amygdala volumes in medication-naïve females with major depressive disorder: a voxel-based morphometric magnetic resonance imaging study. *Psychiatry Research: Neuroimaging* **156**, 83–86.
- van Eijndhoven P, van Wingen G, van Oijen K, Rijpkema M, Goraj B, Jan Verkes R, Oude Voshaar R, Fernández G, Buitelaar J, Tendolkar I (2009). Amygdala volume marks the acute state in the early course of depression. *Biological Psychiatry* **65**, 812–818.
- van Elst LT, Woermann F, Lemieux L, Trimble MR (2000). Increased amygdala volumes in female and depressed humans. A quantitative magnetic resonance imaging study. *Neuroscience Letters* **281**, 103–106.
- Von Gunten A, Fox NC, Cipolotti L, Ron MA (2000). A volumetric study of hippocampus and amygdala in depressed patients with subjective memory problems. *Journal of Neuropsychiatry and Clinical Neurosciences* **12**, 493–498.
- Weniger G, Lange C, Irle E (2006). Abnormal size of the amygdala predicts impaired emotional memory in major depressive disorder. *Journal of Affective Disorders* **94**, 219–229.
- Zou K, Deng W, Li T, Zhang B, Jiang L, Huang C, Sun X, Sun X (2010). Changes of brain morphometry in first-episode, drug-naïve, non-late-life adult patients with major depression: an optimized voxel-based morphometry study. *Biological Psychiatry* **67**, 186–188.